http://jcem.endojournals.org/content/82/11/3793.full
Comparison of self-assessment of libido at the 2 year point showed a dramatic improvement in the testosterone group compared to that in the controls (Fig. 1⇓). The incidence of new illnesses during the course of the study was not significantly different in the two groups for coronary artery disease, peripheral vascular disease, myocardial infarctions, angina, diabetes mellitus, or transient ischemic attacks (Table 3⇓). Benign prostatic hypertrophy (BPH) has long been a concern associated with long term testosterone administration. This study found that the control group had a higher rate of BPH than the study group, but the difference was not statistically significant.
The 2 yr changes in serum and hematocrit values of the two groups are compared in Table 2⇓. There were no significant differences in the prostate-specific antigen concentration. The urea nitrogen to creatinine ratio dropped in the study group, but the change was not statistically significant. Only hematocrit showed a significant increase in the testosterone-treated group compared to that in controls. Eleven subjects (24%) in the testosterone group developed polycythemia (hemoglobin, >17 g/dL; hematocrit, >52%), warranting temporary withdrawal of testosterone therapy or phlebotomy. Of these, the first occurrence of polycythemia was within the first year of therapy in six (33%) subjects, between 1–2 yr in 3 (6.7%) subjects, and beyond 2 yr in two (4.4%) subjects.
Saturday, December 29, 2012
Thursday, December 20, 2012
Testosterone May Benefit Seniors with Chronic Heart Failure
The exercise plus testosterone group experienced improvements from baseline in peak oxygen uptake (P<.01), Beck Depression Inventory (P<.05), leg strength (P<.05) and several Medical Outcomes Study Short-Form quality of life domains (P<.05). These improvements were generally not observed in the exercise plus placebo group, according to the abstract. Similar improvements in shuttle walk test (18% vs. 19%), body mass (–1.3 kg vs. –1 kg) and hand grip strength (2.1 kg vs. 2.5 kg) from baseline to 12 weeks were recorded in both groups.
Testosterone May Benefit Seniors with Chronic Heart Failure
Saturday, December 15, 2012
Should Testosterone Be Tested Under Fasted Conditions?
CONCLUSION: "Until the mechanism behind this effect has been explored, we suggest that assessment of S-T for diagnostic purposes should be collected in the morning after an overnight fasting."
Andrologia. 2012 Dec;44(6):405-10. doi: 10.1111/
S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels.
Lehtihet M, Arver S, Bartuseviciene I, Pousette A.
SourceKarolinska Institute, Centre for Andrology and Sexual Medicine, Karolinska University Hospital, Stockholm, Sweden.
Abstract
Reproducible and accurate assessment of serum testosterone (S-T), S-LH and S-SHBG is of crucial importance for assessment of testicular endocrine function and diagnosis of hypogonadism and investigating male health in a broader sense. Testosterone secretion has a circadian rhythm with the highest component in the morning and is influenced by a series of factors including physical activity, mental stress and nutrition. For diagnostic purposes, analysis of morning samples is recommended and reference values are generally based on samples drawn between 7 and 10 am. In the literature, there are also indications that food intake can influence serum levels but fasting has not been a standard procedure.
To carefully address the influence of food intake, we analysed S-testosterone, S-LH and S-SHBG after an overnight fasting compared to samples taken after a standard meal of 550 kcal.
We found no change in S-LH or S-SHBG but a decline of S-T of 30% from 60 to 120 min after food intake compared to samples taken in the fasting state. This decline may give false low S-T values and overestimate the number of men with suspected hypogonadism. Until the mechanism behind this effect has been explored, we suggest that assessment of S-T for diagnostic purposes should be collected in the morning after an overnight fasting.
Andrologia. 2012 Dec;44(6):405-10. doi: 10.1111/
S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels.
Lehtihet M, Arver S, Bartuseviciene I, Pousette A.
SourceKarolinska Institute, Centre for Andrology and Sexual Medicine, Karolinska University Hospital, Stockholm, Sweden.
Abstract
Reproducible and accurate assessment of serum testosterone (S-T), S-LH and S-SHBG is of crucial importance for assessment of testicular endocrine function and diagnosis of hypogonadism and investigating male health in a broader sense. Testosterone secretion has a circadian rhythm with the highest component in the morning and is influenced by a series of factors including physical activity, mental stress and nutrition. For diagnostic purposes, analysis of morning samples is recommended and reference values are generally based on samples drawn between 7 and 10 am. In the literature, there are also indications that food intake can influence serum levels but fasting has not been a standard procedure.
To carefully address the influence of food intake, we analysed S-testosterone, S-LH and S-SHBG after an overnight fasting compared to samples taken after a standard meal of 550 kcal.
We found no change in S-LH or S-SHBG but a decline of S-T of 30% from 60 to 120 min after food intake compared to samples taken in the fasting state. This decline may give false low S-T values and overestimate the number of men with suspected hypogonadism. Until the mechanism behind this effect has been explored, we suggest that assessment of S-T for diagnostic purposes should be collected in the morning after an overnight fasting.
Wednesday, December 12, 2012
Nelson's Tips and Suggested Supplements
Here are some tips and suggestions :
Supplements:
Zinc/Copper: One, twice a day with food (this supports healthy testosterone and low chances for acne): http://www.amazon.com/Jarrow-Zinc-Balance-100-caps/dp/B001602A10/ref=sr_1_2?ie=UTF8&s=hpc&qid=1302649942&sr=8-2
Multivitamin one after breakfast and lunch: http://www.amazon.com/Super-Nutrition-Energy-vegetarian-capsules/dp/B00028PI16/ref=sr_1_10?s=hpc&ie=UTF8&qid=1302650064&sr=1-10
Carnitine, 1000 mg with breakfast and 1000 mg with lunch:
Vitamin D (4000 IU per day):
Coenzyme Q-10 (200 mg per day):
http://www.amazon.com/Jarrow-Formulas-Q-Absorb-Co-Q10-Softgels/dp/B000U67W8W/ref=sr_1_1?ie=UTF8&qid=1355366495&sr=8-1&keywords=jarrow+coenzyme+q10
Omega 3 (2000-4000 mg/day):
http://www.amazon.com/Nordic-Naturals-Omega-3-Formula-180-Count/dp/B002CQU55K/ref=sr_1_1?s=hpc&ie=UTF8&qid=1355366919&sr=1-1&keywords=omega+3+lemon
Omega 3 (2000-4000 mg/day):
http://www.amazon.com/Nordic-Naturals-Omega-3-Formula-180-Count/dp/B002CQU55K/ref=sr_1_1?s=hpc&ie=UTF8&qid=1355366919&sr=1-1&keywords=omega+3+lemon
Whey Protein (1 or 2 servings a day, no need for a blender- This is the most tolerable and light of all)
Creatine (5 grams per day, two hours before exercise- NOT for people with kidney dysfunction)
Pill box:
Sunday, December 9, 2012
Find the best drug prices from verified online pharmacies
PharmacyChecker.com was founded by a medical doctor in 2003 to help consumers safely save money on medication by identifying the lowest drug prices from reputable online pharmacies. It independently checks the credentials of online pharmacies and lets you easily compare drug prices. Its online pharmacy verification program and drug price comparisons have been referenced by AARP, Smart Money, U.S. News and World Report, and many others.
http://www.pharmacychecker.com/
http://www.pharmacychecker.com/
Testosterone Therapy in Men With Prostate Cancer: Scientific and Ethical Considerations
Morgentaler A. Testosterone Therapy in Men With Prostate Cancer: Scientific and Ethical Considerations. The Journal of Urology 2013;189(1, Supplement):S26-S33. http://www.sciencedirect.com/
P
urpose Pertinent literature regarding the potential use of testosterone therapy in men with prostate cancer is reviewed and synthesized.
Materials and Methods A literature search was performed of English language publications on testosterone administration in men with a known history of prostate cancer and investigation of the effects of androgen concentrations on prostate parameters, especially prostate specific antigen.
Results The prohibition against the use of testosterone therapy in men with a history of prostate cancer is based on a model that assumes the androgen sensitivity of prostate cancer extends throughout the range of testosterone concentrations. Although it is clear that prostate cancer is exquisitely sensitive to changes in serum testosterone at low concentrations, there is considerable evidence that prostate cancer growth becomes androgen indifferent at higher concentrations. The most likely mechanism for this loss of androgen sensitivity at higher testosterone concentrations is the finite capacity of the androgen receptor to bind androgen. This saturation model explains why serum testosterone appears unrelated to prostate cancer risk in the general population and why testosterone administration in men with metastatic prostate cancer causes rapid progression in castrated but not hormonally intact men. Worrisome features of prostate cancer such as high Gleason score, extracapsular disease and biochemical recurrence after surgery have been reported in association with low but not high testosterone. In 6 uncontrolled studies results of testosterone therapy have been reported after radical prostatectomy, external beam radiation therapy or brachytherapy. In a total of 111 men 2 (1.8%) biochemical recurrences were observed. Anecdotal evidence suggests that testosterone therapy does not necessarily cause increased prostate specific antigen even in men with untreated prostate cancer.
Conclusions Although no controlled studies have been performed to date to document the safety of testosterone therapy in men with prostate cancer, the limited available evidence suggests that such treatment may not pose an undue risk of prostate cancer recurrence or progression.
Materials and Methods A literature search was performed of English language publications on testosterone administration in men with a known history of prostate cancer and investigation of the effects of androgen concentrations on prostate parameters, especially prostate specific antigen.
Results The prohibition against the use of testosterone therapy in men with a history of prostate cancer is based on a model that assumes the androgen sensitivity of prostate cancer extends throughout the range of testosterone concentrations. Although it is clear that prostate cancer is exquisitely sensitive to changes in serum testosterone at low concentrations, there is considerable evidence that prostate cancer growth becomes androgen indifferent at higher concentrations. The most likely mechanism for this loss of androgen sensitivity at higher testosterone concentrations is the finite capacity of the androgen receptor to bind androgen. This saturation model explains why serum testosterone appears unrelated to prostate cancer risk in the general population and why testosterone administration in men with metastatic prostate cancer causes rapid progression in castrated but not hormonally intact men. Worrisome features of prostate cancer such as high Gleason score, extracapsular disease and biochemical recurrence after surgery have been reported in association with low but not high testosterone. In 6 uncontrolled studies results of testosterone therapy have been reported after radical prostatectomy, external beam radiation therapy or brachytherapy. In a total of 111 men 2 (1.8%) biochemical recurrences were observed. Anecdotal evidence suggests that testosterone therapy does not necessarily cause increased prostate specific antigen even in men with untreated prostate cancer.
Conclusions Although no controlled studies have been performed to date to document the safety of testosterone therapy in men with prostate cancer, the limited available evidence suggests that such treatment may not pose an undue risk of prostate cancer recurrence or progression.
Saturday, December 1, 2012
Free Androgel and Other Testosterone Products for Men
Here is a table showing all patient assistance programs for different testosterone products in the United States
CLICK HERE
CLICK HERE
Subscribe to:
Posts (Atom)
Register in our new forum site
